FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123664110> ?p ?o ?g. }

• W3123664110 endingPage "1065" @default.
• W3123664110 startingPage "1053" @default.
• W3123664110 abstract "Long non-coding RNAs (lncRNAs) can play significant regulatory roles in cells that affect the development and acquired drug resistance of lung cancer. Herein, we report that lncRNA linc00665 is significantly upregulated in non-small cell lung cancer (NSCLC) tissues compared with adjacent normal tissues. linc00665 affects the sensitivity of NSCLC cells to the chemotherapy drug cisplatin (DDP), making it a potential target for the treatment of NSCLC. Functional experiments showed that linc00665 enhanced the proliferation and migration of NSCLC cells in vivo and in vitro, and knocking down linc00665 could enhance the drug sensitivity of NSCLC cells to DDP. Further work revealed that linc00665 could recruit enhancer of zeste homolog 2 (EZH2) to the promoter region of cyclin-dependent kinase inhibitor 1C (CDKN1C) to inhibit its transcription and thus carry out its tumorigenic role. In conclusion, our study elucidated the carcinogenic role of the linc00665-EZH2-CDKN1C axis in NSCLC tumors and its ability to influence the sensitivity of these tumors to DDP. These results suggest that linc00665 may be a potential diagnostic marker and therapeutic target in NSCLC, and they also provide a new direction for the development of clinical reversal methods for acquired drug resistance in patients with NSCLC. Long non-coding RNAs (lncRNAs) can play significant regulatory roles in cells that affect the development and acquired drug resistance of lung cancer. Herein, we report that lncRNA linc00665 is significantly upregulated in non-small cell lung cancer (NSCLC) tissues compared with adjacent normal tissues. linc00665 affects the sensitivity of NSCLC cells to the chemotherapy drug cisplatin (DDP), making it a potential target for the treatment of NSCLC. Functional experiments showed that linc00665 enhanced the proliferation and migration of NSCLC cells in vivo and in vitro, and knocking down linc00665 could enhance the drug sensitivity of NSCLC cells to DDP. Further work revealed that linc00665 could recruit enhancer of zeste homolog 2 (EZH2) to the promoter region of cyclin-dependent kinase inhibitor 1C (CDKN1C) to inhibit its transcription and thus carry out its tumorigenic role. In conclusion, our study elucidated the carcinogenic role of the linc00665-EZH2-CDKN1C axis in NSCLC tumors and its ability to influence the sensitivity of these tumors to DDP. These results suggest that linc00665 may be a potential diagnostic marker and therapeutic target in NSCLC, and they also provide a new direction for the development of clinical reversal methods for acquired drug resistance in patients with NSCLC." @default.
• W3123664110 created "2021-02-01" @default.
• W3123664110 creator A5014096233 @default.
• W3123664110 creator A5020951392 @default.
• W3123664110 creator A5022504184 @default.
• W3123664110 creator A5032803107 @default.
• W3123664110 creator A5046597133 @default.
• W3123664110 creator A5046731778 @default.
• W3123664110 creator A5074934997 @default.
• W3123664110 creator A5081755901 @default.
• W3123664110 creator A5086741446 @default.
• W3123664110 date "2021-03-01" @default.
• W3123664110 modified "2023-09-29" @default.
• W3123664110 title "Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells" @default.
• W3123664110 cites W1571858136 @default.
• W3123664110 cites W1966397536 @default.
• W3123664110 cites W1978068592 @default.
• W3123664110 cites W1989330242 @default.
• W3123664110 cites W2016302314 @default.
• W3123664110 cites W2026805262 @default.
• W3123664110 cites W2097607581 @default.
• W3123664110 cites W2113622484 @default.
• W3123664110 cites W2168848564 @default.
• W3123664110 cites W2278501485 @default.
• W3123664110 cites W2497141050 @default.
• W3123664110 cites W2519566455 @default.
• W3123664110 cites W2542904087 @default.
• W3123664110 cites W2575362904 @default.
• W3123664110 cites W2763759608 @default.
• W3123664110 cites W2766555471 @default.
• W3123664110 cites W2789382357 @default.
• W3123664110 cites W2799684183 @default.
• W3123664110 cites W2809860772 @default.
• W3123664110 cites W2811260579 @default.
• W3123664110 cites W2889438018 @default.
• W3123664110 cites W2912601922 @default.
• W3123664110 cites W2915601187 @default.
• W3123664110 cites W2944329718 @default.
• W3123664110 cites W2982388215 @default.
• W3123664110 cites W3009792585 @default.
• W3123664110 cites W3014506771 @default.
• W3123664110 cites W3017135727 @default.
• W3123664110 cites W3081180354 @default.
• W3123664110 cites W3092406823 @default.
• W3123664110 doi "https://doi.org/10.1016/j.omtn.2021.01.013" @default.
• W3123664110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7887328" @default.
• W3123664110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33664990" @default.
• W3123664110 hasPublicationYear "2021" @default.
• W3123664110 type Work @default.
• W3123664110 sameAs 3123664110 @default.
• W3123664110 citedByCount "24" @default.
• W3123664110 countsByYear W31236641102021 @default.
• W3123664110 countsByYear W31236641102022 @default.
• W3123664110 countsByYear W31236641102023 @default.
• W3123664110 crossrefType "journal-article" @default.
• W3123664110 hasAuthorship W3123664110A5014096233 @default.
• W3123664110 hasAuthorship W3123664110A5020951392 @default.
• W3123664110 hasAuthorship W3123664110A5022504184 @default.
• W3123664110 hasAuthorship W3123664110A5032803107 @default.
• W3123664110 hasAuthorship W3123664110A5046597133 @default.
• W3123664110 hasAuthorship W3123664110A5046731778 @default.
• W3123664110 hasAuthorship W3123664110A5074934997 @default.
• W3123664110 hasAuthorship W3123664110A5081755901 @default.
• W3123664110 hasAuthorship W3123664110A5086741446 @default.
• W3123664110 hasBestOaLocation W31236641101 @default.
• W3123664110 hasConcept C104317684 @default.
• W3123664110 hasConcept C114851261 @default.
• W3123664110 hasConcept C127561419 @default.
• W3123664110 hasConcept C143998085 @default.
• W3123664110 hasConcept C207001950 @default.
• W3123664110 hasConcept C2776256026 @default.
• W3123664110 hasConcept C2776694085 @default.
• W3123664110 hasConcept C2778239845 @default.
• W3123664110 hasConcept C41091548 @default.
• W3123664110 hasConcept C50171091 @default.
• W3123664110 hasConcept C502942594 @default.
• W3123664110 hasConcept C54355233 @default.
• W3123664110 hasConcept C62112901 @default.
• W3123664110 hasConcept C62203573 @default.
• W3123664110 hasConcept C71924100 @default.
• W3123664110 hasConcept C86803240 @default.
• W3123664110 hasConceptScore W3123664110C104317684 @default.
• W3123664110 hasConceptScore W3123664110C114851261 @default.
• W3123664110 hasConceptScore W3123664110C127561419 @default.
• W3123664110 hasConceptScore W3123664110C143998085 @default.
• W3123664110 hasConceptScore W3123664110C207001950 @default.
• W3123664110 hasConceptScore W3123664110C2776256026 @default.
• W3123664110 hasConceptScore W3123664110C2776694085 @default.
• W3123664110 hasConceptScore W3123664110C2778239845 @default.
• W3123664110 hasConceptScore W3123664110C41091548 @default.
• W3123664110 hasConceptScore W3123664110C50171091 @default.
• W3123664110 hasConceptScore W3123664110C502942594 @default.
• W3123664110 hasConceptScore W3123664110C54355233 @default.
• W3123664110 hasConceptScore W3123664110C62112901 @default.
• W3123664110 hasConceptScore W3123664110C62203573 @default.
• W3123664110 hasConceptScore W3123664110C71924100 @default.
• W3123664110 hasConceptScore W3123664110C86803240 @default.
• W3123664110 hasFunder F4320321001 @default.

• next